| Year |
Citation |
Score |
| 2024 |
Kozono D, Hua X, Wu MC, Tolba KA, Waqar SN, Dragnev KH, Cheng H, Hirsch FR, Mack PC, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman MW. Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 39111731 DOI: 10.1016/j.jtho.2024.07.024 |
0.337 |
|
| 2023 |
Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, et al. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 37702631 DOI: 10.1016/j.jtho.2023.07.017 |
0.349 |
|
| 2023 |
Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, ... ... Redman MW, et al. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). Jco Precision Oncology. 7: e2300218. PMID 37677122 DOI: 10.1200/PO.23.00218 |
0.342 |
|
| 2022 |
Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Gandara DR, Kelly K, Herbst RS. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200912. PMID 35658002 DOI: 10.1200/JCO.22.00912 |
0.319 |
|
| 2022 |
Witlox WJA, Ramaekers BLT, Lacas B, Le Pechoux C, Sun A, Wang SY, Hu C, Redman M, van der Noort V, Li N, Guckenberger M, van Tinteren H, Hendriks LEL, Groen HJM, Joore MA, et al. Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 35259416 DOI: 10.1016/j.radonc.2022.02.036 |
0.31 |
|
| 2022 |
Gettinger S, Redman MW, Herbst RS. Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply. Jama Oncology. PMID 35142793 DOI: 10.1001/jamaoncol.2021.7790 |
0.33 |
|
| 2022 |
Jongen A, Charlier F, Baker K, Chang J, Hartsell W, Laramore G, Mohindra P, Moretti L, Redman M, Rosen L, Tsai H, Van Gestel D, Vargas C, Rengan R. Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry. Advances in Radiation Oncology. 7: 100767. PMID 35071826 DOI: 10.1016/j.adro.2021.100767 |
0.332 |
|
| 2021 |
Hirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical Lung Cancer. PMID 34753703 DOI: 10.1016/j.cllc.2021.10.002 |
0.364 |
|
| 2021 |
Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, et al. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal For Immunotherapy of Cancer. 9. PMID 34429332 DOI: 10.1136/jitc-2021-002973 |
0.319 |
|
| 2021 |
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, et al. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 34264316 DOI: 10.1001/jamaoncol.2021.2209 |
0.398 |
|
| 2021 |
Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, ... Redman MW, et al. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clinical Lung Cancer. PMID 33745865 DOI: 10.1016/j.cllc.2021.02.009 |
0.356 |
|
| 2021 |
Witlox WJA, Ramaekers BLT, Lacas B, Le Pechoux C, Pignon JP, Sun A, Wang SY, Hu C, Redman M, van der Noort V, Li N, Guckenberger M, van Tinteren H, Groen HJM, Joore MA, et al. Individual patient data meta-analysis of prophylactic cranial irradiation in locally advanced non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 33587968 DOI: 10.1016/j.radonc.2021.02.002 |
0.365 |
|
| 2021 |
Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, et al. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clinical Lung Cancer. PMID 33583720 DOI: 10.1016/j.cllc.2021.01.001 |
0.329 |
|
| 2021 |
Riess JW, Redman MW, Wheatley-Price P, Faller BA, Villaruz LC, Corum LR, Gowda AC, Srkalovic G, Osarogiagbon RU, Baumgart MA, Qian L, Minichiello K, Gandara DR, Herbst RS, Kelly K. A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A). Journal of Clinical Oncology. 39: 9024-9024. DOI: 10.1200/JCO.2021.39.15_SUPPL.9024 |
0.323 |
|
| 2020 |
Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clinical Lung Cancer. PMID 33358401 DOI: 10.1016/j.cllc.2020.10.015 |
0.33 |
|
| 2020 |
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, et al. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical Lung Cancer. PMID 33221175 DOI: 10.1016/j.cllc.2020.09.013 |
0.307 |
|
| 2020 |
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. The Lancet. Oncology. PMID 33125909 DOI: 10.1016/S1470-2045(20)30475-7 |
0.314 |
|
| 2020 |
Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, et al. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001149. PMID 33021871 DOI: 10.1200/JCO.20.01149 |
0.342 |
|
| 2020 |
Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, Trieselmann K, Copeland VC, Zhang S, Black G, McDonnell S, Gregory J, Johnson R, Moore R, Jones RL, et al. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. Jama Oncology. PMID 32910151 DOI: 10.1001/Jamaoncol.2020.3689 |
0.394 |
|
| 2020 |
Nyame YA, Baker KK, Montgomery RB, Grivas P, Redman MW, Wright JL. Racial and sex differences in somatic mutations in bladder cancer patients: An analysis of the cBioPortal for Cancer Genomics. Journal of Clinical Oncology. 38: 556-556. DOI: 10.1200/Jco.2020.38.6_Suppl.556 |
0.344 |
|
| 2020 |
Chang AE, Zhen DB, Radke M, Baker KK, Coveler AL, Wong KM, Pillarisetty VG, Redman MW, Swisher E, Chiorean EG. Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience. Journal of Clinical Oncology. 38: 732-732. DOI: 10.1200/Jco.2020.38.4_Suppl.732 |
0.31 |
|
| 2020 |
Leighl NB, Redman MW, Rizvi NA, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy S, Crawford J, Bradley JD, Stinchcombe T, Ramalingam SS, Miao J, Minichiello K, et al. SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). Journal of Clinical Oncology. 38: 9623-9623. DOI: 10.1200/Jco.2020.38.15_Suppl.9623 |
0.454 |
|
| 2020 |
Redman MW, Papadimitrakopoulou V, Minichiello K, Gandara DR, Hirsch FR, Mack PC, Schwartz LH, Vokes EE, Ramalingam SS, Leighl NB, Bradley J, LeBlanc ML, Malik S, Miller VA, Sigal EV, et al. Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). Journal of Clinical Oncology. 38: 9576-9576. DOI: 10.1200/Jco.2020.38.15_Suppl.9576 |
0.402 |
|
| 2020 |
Mack PC, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MAC, Walther Z, Hirsch FR, Politi KA, Kelly K, Gandara DR. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Journal of Clinical Oncology. 38: 9532-9532. DOI: 10.1200/Jco.2020.38.15_Suppl.9532 |
0.443 |
|
| 2019 |
Kargl J, Zhu X, Zhang H, Yang GHY, Friesen TJ, Shipley M, Maeda DY, Zebala JA, McKay-Fleisch J, Meredith G, Mashadi-Hossein A, Baik C, Pierce RH, Redman MW, Thompson JC, et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. Jci Insight. 4. PMID 31852845 DOI: 10.1172/Jci.Insight.130850 |
0.373 |
|
| 2019 |
Zhao YQ, Redman MW, LeBlanc ML. Quantifying treatment effects using the personalized chance of longer survival. Statistics in Medicine. PMID 31502297 DOI: 10.1002/Sim.8363 |
0.323 |
|
| 2019 |
Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900269. PMID 31386610 DOI: 10.1200/Jco.19.00269 |
0.367 |
|
| 2019 |
Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology. Blood Advances. 3: 2237-2243. PMID 31337605 DOI: 10.1182/Bloodadvances.2019031229 |
0.386 |
|
| 2019 |
Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31302234 DOI: 10.1016/J.Jtho.2019.06.027 |
0.464 |
|
| 2019 |
Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31195180 DOI: 10.1016/J.Jtho.2019.05.041 |
0.456 |
|
| 2019 |
Langer CJ, Redman MW, Wade JL, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA. Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31158500 DOI: 10.1016/J.Jtho.2019.05.029 |
0.435 |
|
| 2019 |
Symonds LK, Baker KK, Redman MW, Koch L, Carter K, Yu M, Wirtz R, Poulios C, Pentheroudakis GE, Papaxoinis G, Pectasides DG, Kalogeras KT, Fountzilas G, Grady WM, Cohen S. MACC1 expression as a candidate prognostic biomarker in colorectal cancer patients receiving adjuvant oxaliplatin-based therapy. Journal of Clinical Oncology. 37: 567-567. DOI: 10.1200/Jco.2019.37.4_Suppl.567 |
0.35 |
|
| 2019 |
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe T, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Kelly K, Bradley JD, et al. Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). Journal of Clinical Oncology. 37: 9075-9075. DOI: 10.1200/Jco.2019.37.15_Suppl.9075 |
0.44 |
|
| 2019 |
Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe T, Leighl NB, Baghdadi TA, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, et al. A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). Journal of Clinical Oncology. 37: 9022-9022. DOI: 10.1200/Jco.2019.37.15_Suppl.9022 |
0.46 |
|
| 2019 |
Bazhenova L, Redman MW, Gettinger SN, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Bradley JD, Stinchcombe T, Leighl NB, Ramalingam SS, Tavernier SS, Minichiello K, Kelly K, Papadimitrakopoulou V, et al. A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). Journal of Clinical Oncology. 37: 9014-9014. DOI: 10.1200/Jco.2019.37.15_Suppl.9014 |
0.437 |
|
| 2019 |
Argiris A, Miao J, Cristea MC, Chen AM, Sands J, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, ... Redman MW, et al. S1206: A dose-finding study followed by a phase II randomized placebo-controlled trial of chemoradiotherapy (CRT) with or without veliparib in stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 37: 8523-8523. DOI: 10.1200/Jco.2019.37.15_Suppl.8523 |
0.332 |
|
| 2019 |
Pollack S, Redman MW, Wagner M, Loggers ET, Baker KK, McDonnell S, Gregory J, Copeland VC, Hammer KJ, Johnson R, Moore R, Shahnazari M, Townson SM, Jones RL, Cranmer LD. A phase I/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with metastatic/unresectable sarcoma. Journal of Clinical Oncology. 37: 11009-11009. DOI: 10.1200/Jco.2019.37.15_Suppl.11009 |
0.378 |
|
| 2019 |
Witlox W, Ruysscher DD, Lacas B, Pechoux CL, Pignon J, Guckenberger M, Sun A, Redman M, Wang S, Hu C, Noort VVd, Li N, Tinteren HV, Groen H, Joore M, et al. PCI for Radically Treated Non-Small Cell Lung Cancer: A Meta-Analysis Using Updated Individual Patient Data of Randomized Trials Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.471 |
0.457 |
|
| 2019 |
Roth J, Trivedi M, Gray S, Patrick D, Burke W, Delaney D, Watabayashi K, Litwin P, Shah P, Crew K, Yee M, Redman M, Papadimitrakopoulou V, Kelly K, Gandara D, et al. OA07.06 Patient Knowledge and Expectations Related to Return of Genomic Results in the Lung-MAP (SWOG 1400) Biomarker-Driven Clinical Trial Journal of Thoracic Oncology. 14: S224-S225. DOI: 10.1016/J.Jtho.2019.08.445 |
0.382 |
|
| 2019 |
Bazhenova L, Redman M, Gettinger S, Hirsch FR, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, et al. OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.423 |
0.456 |
|
| 2019 |
Mino-Kenudson M, Redman M, Hedger J, Daigneault J, Botling J, Brambilla E, Chen G, Chou T, Cooper W, Hirsch F, Jain D, Kerr K, Longshore J, Lopez-Rios F, Motoi N, et al. P2.09-24 IASLC Global Survey for Pathologists on PD-L1 Testing for Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14: S778-S779. DOI: 10.1016/J.Jtho.2019.08.1673 |
0.347 |
|
| 2018 |
Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C, et al. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Clinical Breast Cancer. PMID 30737173 DOI: 10.1016/J.Clbc.2018.12.008 |
0.342 |
|
| 2018 |
Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, ... ... Redman MW, et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30268698 DOI: 10.1016/J.Jtho.2018.09.017 |
0.444 |
|
| 2018 |
Cook M, Baker K, Redman M, Lachance K, Nguyen MH, Parvathaneni U, Bhatia S, Nghiem P, Tseng YD. Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival. American Journal of Clinical Oncology. PMID 30211723 DOI: 10.1097/Coc.0000000000000482 |
0.375 |
|
| 2018 |
Tseng YD, Nguyen MH, Baker K, Cook M, Redman M, Lachance K, Bhatia S, Liao JJ, Apisarnthanarax S, Nghiem PT, Parvathaneni U. Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma. International Journal of Radiation Oncology, Biology, Physics. 102: 330-339. PMID 30191867 DOI: 10.1016/J.Ijrobp.2018.05.075 |
0.35 |
|
| 2018 |
Rengan R, Redman M, Zeng J. Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018783803. PMID 29746228 DOI: 10.1200/Jco.2018.78.3803 |
0.402 |
|
| 2018 |
Guerriero MK, Redman MW, Baker KK, Martins RG, Eaton K, Chow LQ, Santana-Davila R, Baik C, Goulart BH, Lee S, Rodriguez CP. Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial. Cancer. PMID 29669181 DOI: 10.1002/Cncr.31407 |
0.37 |
|
| 2018 |
Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, et al. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). Journal of the National Cancer Institute. PMID 29346580 DOI: 10.1093/Jnci/Djx260 |
0.343 |
|
| 2018 |
Papadimitrakopoulou V, Redman MW, Gandara DR, Hirsch FR, Mack PC, Langer CJ, Edelman MJ, Aggarwal C, Socinski MA, Gettinger SN, Waqar SN, Griffin K, Leighl NB, Owonikoko TK, Bradley JD, et al. First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. Journal of Clinical Oncology. 36: 9019-9019. DOI: 10.1200/Jco.2018.36.15_Suppl.9019 |
0.405 |
|
| 2018 |
Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach J, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel SM, Redman MW, Gandara DR, Kelly K. SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 36: 8514-8514. DOI: 10.1200/Jco.2018.36.15_Suppl.8514 |
0.359 |
|
| 2018 |
Goldberg S, Redman M, Lilenbaum R, Politi K, Stinchcombe T, Horn L, Chen E, Mashru S, Gettinger S, Melnick MA, Miao J, Moon J, Kelly K, Gandara D. OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403 Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.290 |
0.408 |
|
| 2017 |
Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet. Oncology. PMID 29169877 DOI: 10.1016/S1470-2045(17)30694-0 |
0.462 |
|
| 2017 |
West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clinical Lung Cancer. PMID 28801183 DOI: 10.1016/J.Cllc.2017.06.016 |
0.456 |
|
| 2017 |
Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K. Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28599887 DOI: 10.1016/J.Jtho.2017.05.021 |
0.307 |
|
| 2017 |
Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases. Clinical Epigenetics. 9: 46. PMID 28469732 DOI: 10.1186/S13148-017-0347-1 |
0.345 |
|
| 2017 |
Chang AE, Shahda S, Harris WP, Cohen S, Coveler AL, O'Neil BH, Gadi VK, Hibbert R, Lee HH, Younger A, McCormick KA, Pritchard C, Redman MW, Chiorean EG. Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.4_Suppl.Tps515 |
0.436 |
|
| 2017 |
Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique N, Petro DP, Waqar SN, Miao J, Griffin K, Papadimitrakopoulou V, Kelly K, Gandara DR, Herbst RS. A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. Journal of Clinical Oncology. 35: 9056-9056. DOI: 10.1200/Jco.2017.35.15_Suppl.9056 |
0.446 |
|
| 2017 |
Aggarwal C, Redman MW, Lara P, Borghaei H, Hoffman PC, Bradley JD, Griffin K, Miao J, Mack PC, Papadimitrakopoulou V, Herbst RS, Kelly K, Gandara DR. Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. Journal of Clinical Oncology. 35: 9055-9055. DOI: 10.1200/Jco.2017.35.15_Suppl.9055 |
0.477 |
|
| 2017 |
Wade JL, Langer CJ, Redman M, Aggarwal C, Bradley JD, Crawford J, Miao J, Griffin K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou V. A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. Journal of Clinical Oncology. 35: 9054-9054. DOI: 10.1200/Jco.2017.35.15_Suppl.9054 |
0.456 |
|
| 2017 |
Liao JB, Cecil DL, Dang Y, Baker KK, Ovenell KJ, Reichow J, Parker S, Higgins DM, Childs JS, Broussard EK, Coveler AL, Salazar LG, Goff BA, Redman MW, Disis ML. Abstract NTOC-097: VACCINATION TARGETING INSULIN–LIKE GROWTH FACTOR BINDING PROTEIN–2 (IGFBP–2) IN ADVANCED OVARIAN CANCER: SAFETY, IMMUNOGENICITY, AND SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) COMPARISON Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ntoc-097 |
0.36 |
|
| 2017 |
Specht J, Gadi V, Gralow J, Korde L, Linden H, Salazar L, Rodler E, Cundy A, Buening B, Baker K, Redman M, Kurland B, Garrison M, Smith J, vanHaelst C, et al. Abstract P4-22-11: Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-22-11 |
0.324 |
|
| 2017 |
Papadimitrakopoulou V, Redman MW, Borghaei H, Waqar SN, Robert F, Kiefer GJ, McDonough S, Herbst RS, Kelly K, Gandara DR. 83OA phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx091.003 |
0.41 |
|
| 2017 |
Geiger C, Baker K, Redman M, Goulart B, Eaton K, Martins R, Baik C. P1.06-009 Barriers to Clinical Trial Participation in Lung Cancer Patients, a Single Institution Experience Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.903 |
0.416 |
|
| 2017 |
Herbst R, Redman M, Gandara DR, Hirsch FR, Mack P, Borghaei H, Langer C, Wade J, Engelman J, Edelman M, Albain K, Lara P, Aggarwal C, Socinski M, Gettinger S, et al. OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.412 |
0.371 |
|
| 2017 |
Mack P, Miao J, Banks K, Burich R, Politi K, Raymond V, Dix D, Lanman R, Moon J, Melnick MA, Truini A, Redman M, Goldberg S, Gandara DR, Kelly K. P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1487 |
0.346 |
|
| 2017 |
Lara P, Miao J, Moon J, Redman M, Gandara DR, Kelly K. MA11.06 SWOG 0124: Platinum-Sensitivity Status and Post-Progression Survival in Patients with Extensive-Stage Small Cell Lung Cancer Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.465 |
0.458 |
|
| 2017 |
Goldberg S, Moon J, Lilenbaum R, Politi K, Melnick MA, Stinchcombe T, Horn L, Chen E, Miao J, Redman M, Kelly K, Gandara DR. P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403: Topic: EGFR Clinical Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1719 |
0.333 |
|
| 2017 |
Mack P, Moon J, Herbst R, Kim E, Semrad T, Redman M, Tsai R, Solis L, Gregg J, Hatcher S, Varella-Garcia M, Hirsch FR, Blanke C, Kelly K, Gandara DR. P2.03b-053 Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab: Topic: Biomarkers Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1334 |
0.401 |
|
| 2016 |
Pellini Ferreira B, Redman M, Baker KK, Martins R, Eaton KD, Chow LQ, Baik CS, Goulart B, Lee SM, Santana-Davila R, Rodriguez CP. Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. The Laryngoscope. PMID 27905113 DOI: 10.1002/Lary.26422 |
0.301 |
|
| 2016 |
Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, et al. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27646951 DOI: 10.1200/Jco.2016.67.7088 |
0.428 |
|
| 2016 |
Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, ... ... Redman MW, et al. Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27013409 DOI: 10.1016/J.Jtho.2016.03.012 |
0.439 |
|
| 2016 |
Hirsch FR, Redman MW, Herbst RS, Kim ES, Semrad TJ, Bazhenova L, Masters GA, Oettel KR, Guaglianone P, Reynolds CM, Karnad AB, Arnold SM, Varella-Garcia M, Moon J, Mack PC, et al. Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. Journal of Clinical Oncology. 34: 9090-9090. DOI: 10.1200/Jco.2016.34.15_Suppl.9090 |
0.406 |
|
| 2016 |
Papadimitrakopoulou V, Redman M, Gandara DR, Hirsch FR, Mack PC, Borghaei H, Langer CJ, Engelman JA, Edelman MJ, Albain KS, Lara P, Aggarwal C, Socinski MA, Gettinger SN, Bazhenova L, et al. Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. Journal of Clinical Oncology. 34: 9088-9088. DOI: 10.1200/Jco.2016.34.15_Suppl.9088 |
0.379 |
|
| 2016 |
Semrad TJ, Redman MW, Herbst RS, Kim ES, Bazhenova L, Masters GA, Oettel KR, Guaglianone P, Reynolds CM, Karnad AB, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, et al. Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9082-9082. DOI: 10.1200/Jco.2016.34.15_Suppl.9082 |
0.458 |
|
| 2016 |
Kendrick MW, Redman MW, Baker KK, Martins RG, Eaton KD, Chow LQM, Santana-Davila R, Baik CS, Goulart BHL, Lee SM, Rodriguez CP. Racial disparity in oncologic and patient-reported quality of life (PROs) outcomes in patients with locally advanced head and neck squamous cell carcinomas (HNSCC) enrolled in a randomized phase II trial. Journal of Clinical Oncology. 34: 6048-6048. DOI: 10.1200/Jco.2016.34.15_Suppl.6048 |
0.381 |
|
| 2015 |
Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib Versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 26725184 DOI: 10.1016/J.Jtho.2015.11.003 |
0.499 |
|
| 2015 |
Gandara DR, Redman M, Hirsch FR. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. Jama Oncology. 1-2. PMID 26720042 DOI: 10.1001/Jamaoncol.2015.4920 |
0.433 |
|
| 2015 |
Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clinical Lung Cancer. PMID 26498504 DOI: 10.1016/J.Cllc.2015.09.003 |
0.465 |
|
| 2015 |
Redman MW, Allegra CJ. The Master Protocol Concept. Seminars in Oncology. 42: 724-30. PMID 26433553 DOI: 10.1053/J.Seminoncol.2015.07.009 |
0.304 |
|
| 2015 |
Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP--framework, overview, and design principles. Chinese Clinical Oncology. 4: 36. PMID 26408303 DOI: 10.3978/J.Issn.2304-3865.2015.09.02 |
0.471 |
|
| 2015 |
Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 1099-106. PMID 26134227 DOI: 10.1097/Jto.0000000000000548 |
0.462 |
|
| 2015 |
Lara PN, Gandara DR, Redman MW. Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer". Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: e36. PMID 25898968 DOI: 10.1097/Jto.0000000000000515 |
0.438 |
|
| 2015 |
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, et al. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1514-24. PMID 25680375 DOI: 10.1158/1078-0432.Ccr-13-3473 |
0.443 |
|
| 2015 |
Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. Clinical Pharmacology and Therapeutics. 97: 488-91. PMID 25676724 DOI: 10.1002/Cpt.88 |
0.486 |
|
| 2015 |
Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 110-5. PMID 25490004 DOI: 10.1097/Jto.0000000000000385 |
0.429 |
|
| 2015 |
Ferreira BP, Baker KK, Redman M, Martins R, Eaton KD, Chow LQM, Baik CS, Goulart B, Lee SM, Santana-Davila R, Rodriguez CP. Predictors of outcome in patients with recurrent/metastatic head and neck squamous cell carcinomas (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E17065 |
0.375 |
|
| 2015 |
Araki D, Redman MW, Martins R, Eaton KD, Baik CS, Chow LQM, Goulart B, Lee SM, Santana-Davila R, Liao JJ, Parvathaneni U, Futran N, Mendez E, Rodriguez CP. Cetuximab concurrent with postoperative radiation (Cet-XRT) in poor risk patients with resected squamous cell carcinomas of the head and neck (SCCHN). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E17037 |
0.359 |
|
| 2015 |
Lara P, Moon J, Hesketh PJ, Redman MW, Williamson SK, Hirsch FR, Mack PC, Gandara DR. SWOG 0709: A randomized phase II “pick-the-winner” trial of erlotinib (ERL) vs. ERL plus carboplatin/paclitaxel (C/T) in patients (pts) with advanced non-small cell lung cancer (NSCLC) and impaired performance status (PS 2) as selected by serum proteomics. Journal of Clinical Oncology. 33: 8040-8040. DOI: 10.1200/Jco.2015.33.15_Suppl.8040 |
0.407 |
|
| 2014 |
Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2463-70. PMID 25002722 DOI: 10.1200/Jco.2013.51.4109 |
0.476 |
|
| 2014 |
Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer. 120: 2343-51. PMID 24752945 DOI: 10.1002/Cncr.28714 |
0.477 |
|
| 2014 |
Dias MM, Pignon JP, Karapetis CS, Boige V, Glimelius B, Kweekel DM, Lara PN, Laurent-Puig P, Martinez-Balibrea E, Páez D, Punt CJA, Redman MW, Toffoli G, Wadelius M, Mckinnon RA, et al. The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis Pharmacogenomics Journal. 14: 424-431. PMID 24709690 DOI: 10.1038/Tpj.2014.16 |
0.367 |
|
| 2014 |
Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clinical Lung Cancer. 15: 1-6. PMID 24176733 DOI: 10.1016/J.Cllc.2013.10.001 |
0.402 |
|
| 2014 |
Cho E, Rubinstein L, Redman MW, Rockhill J, Halasz LM, Gensheimer M, Phillips M, Linden HM, Gadi VK. Differentiation of overall survival by breast cancer tumor subtype following stereotactic radiosurgery for brain metastasis. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E11584 |
0.313 |
|
| 2013 |
Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 1519-28. PMID 24189513 DOI: 10.1097/Jto.0000000000000009 |
0.459 |
|
| 2013 |
Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Frontiers in Oncology. 3: 219. PMID 24010120 DOI: 10.3389/Fonc.2013.00219 |
0.463 |
|
| 2013 |
Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2646-56. PMID 23669424 DOI: 10.1158/1078-0432.Ccr-12-2939 |
0.339 |
|
| 2013 |
Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clinical Lung Cancer. 14: 351-5. PMID 23415808 DOI: 10.1016/J.Cllc.2012.12.004 |
0.481 |
|
| 2013 |
Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR. A phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905). Journal of Clinical Oncology. 31: 7527-7527. DOI: 10.1200/Jco.2013.31.15_Suppl.7527 |
0.365 |
|
| 2013 |
Lara P, Moon J, Redman MW, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. Relevance of platinum (plat) sensitivity status in previously treated extensive-stage small cell lung cancer (ES-SCLC) in the modern era: A patient level analysis of SWOG trials. Journal of Clinical Oncology. 31: 7511-7511. DOI: 10.1200/Jco.2013.31.15_Suppl.7511 |
0.411 |
|
| 2013 |
Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis. Journal of Clinical Oncology. 31: 7510-7510. DOI: 10.1200/Jco.2013.31.15_Suppl.7510 |
0.428 |
|
| 2012 |
Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clinical Lung Cancer. 13: 321-5. PMID 22677432 DOI: 10.1016/J.Cllc.2012.05.004 |
0.44 |
|
| 2012 |
Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4004-12. PMID 22592956 DOI: 10.1158/1078-0432.Ccr-12-0167 |
0.388 |
|
| 2012 |
Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA, Mandrekar SJ. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer. 118: 5358-65. PMID 22434489 DOI: 10.1002/Cncr.27528 |
0.381 |
|
| 2012 |
Hesketh PJ, Redman MW, Unger JM, Moon J, Gandara DR. Older patient participation in SWOG lung cancer trials: Comparative analysis from 1993 to 2008. Journal of Clinical Oncology. 30: 7570-7570. DOI: 10.1200/Jco.2012.30.15_Suppl.7570 |
0.44 |
|
| 2012 |
Mack PC, Moon J, West HJ, Franklin WA, Varella-Garcia M, Wynes MW, Wozniak AJ, Redman MW, Hirsch FR, Gandara DR. Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC. Journal of Clinical Oncology. 30: 7552-7552. DOI: 10.1200/Jco.2012.30.15_Suppl.7552 |
0.378 |
|
| 2012 |
West HJ, Moon J, Hirsch FR, Mack PC, Wozniak AJ, Lau D, Fehrenbacher L, Bury MJ, Redman MW, Gandara DR. SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). Journal of Clinical Oncology. 30: 7517-7517. DOI: 10.1200/Jco.2012.30.15_Suppl.7517 |
0.444 |
|
| 2011 |
Mandrekar SJ, Qi Y, Allen-Ziegler K, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA. Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7005. PMID 28020086 DOI: 10.1200/Jco.2011.29.15_Suppl.7005 |
0.448 |
|
| 2011 |
Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DR. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1938-45. PMID 21964533 DOI: 10.1097/Jto.0B013E318229586E |
0.411 |
|
| 2011 |
Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 598-601. PMID 21270668 DOI: 10.1097/Jto.0B013E318208C83D |
0.31 |
|
| 2010 |
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4747-54. PMID 20921467 DOI: 10.1200/Jco.2009.27.9356 |
0.491 |
|
| 2010 |
Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara DR. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 116: 5710-5. PMID 20737417 DOI: 10.1002/Cncr.25532 |
0.463 |
|
| 2010 |
Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O'Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3611-6. PMID 20606094 DOI: 10.1200/Jco.2009.25.8285 |
0.336 |
|
| 2010 |
Mack PC, Redman MW, Chansky K, Matsumoto S, Holland WS, Lara P, Ambrosone CB, Gandara DR. KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424. Journal of Clinical Oncology. 28: 7013-7013. DOI: 10.1200/Jco.2010.28.15_Suppl.7013 |
0.307 |
|
| 2009 |
Garland LL, Chansky K, Wozniak A, Tsao A, Gadgeel S, Vershraegen C, Da Silva M, Redman M, Gandara D. SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7511. PMID 27963482 DOI: 10.1200/Jco.2009.27.15_Suppl.7511 |
0.307 |
|
| 2009 |
Franklin WA, Gandara DR, Kim ES, Herbst RS, Moon J, Redman MW, Olsen C, Hirsch FR, Mack P, Kelly K. SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11076. PMID 27963196 DOI: 10.1200/Jco.2009.27.15_Suppl.11076 |
0.427 |
|
| 2009 |
Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K. S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8015. PMID 27962808 DOI: 10.1200/Jco.2009.27.15_Suppl.8015 |
0.459 |
|
| 2009 |
Mack PC, Holland WS, Redman M, Lara PN, Snyder LJ, Hirsch FR, Franklin WA, Kim ES, Herbst RS, Gandara DR. KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8022. PMID 27962804 DOI: 10.1200/Jco.2009.27.15_Suppl.8022 |
0.439 |
|
| 2009 |
Le QT, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Gandara DR. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3014-9. PMID 19364954 DOI: 10.1200/Jco.2008.21.3868 |
0.468 |
|
| 2009 |
Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2530-5. PMID 19349543 DOI: 10.1200/Jco.2008.20.1061 |
0.446 |
|
| 2009 |
Lara P, Chansky K, Shibata T, Fukuda H, Tamura T, Saijo N, Redman M, Lenz HJ, Natale R, Gandara DR. Cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer (E-SCLC): Final “common arm”: Comparative outcomes analysis of JCOG 9511 and SWOG 0124 Journal of Clinical Oncology. 27: 8027-8027. DOI: 10.1200/Jco.2009.27.15_Suppl.8027 |
0.462 |
|
| 2008 |
Le Q, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar L, Crowley JJ, Moore DF, Gandara DR. SWOG 0222: A phase II study of tirapazamine (NSC-130181, TPZ)/cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (TRT) for limited stage small-cell lung cancer (LSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7523. PMID 27947202 DOI: 10.1200/Jco.2008.26.15_Suppl.7523 |
0.442 |
|
| 2008 |
Shepherd BE, Redman MW, Ankerst DP. Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. Journal of the American Statistical Association. 103: 1392-1404. PMID 20526381 DOI: 10.1198/016214508000000706 |
0.328 |
|
| 2008 |
Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prevention Research (Philadelphia, Pa.). 1: 174-81. PMID 19138953 DOI: 10.1158/1940-6207.Capr-08-0092 |
0.303 |
|
| 2008 |
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4771-6. PMID 18779603 DOI: 10.1200/Jco.2008.17.0662 |
0.415 |
|
| 2008 |
Misono SN, Weiss NS, Fann JR, Redman M, Yueh B. Incidence of suicide in persons with cancer. Journal of Clinical Oncology. 26: 4731-4738. PMID 18695257 DOI: 10.1200/Jco.2007.13.8941 |
0.347 |
|
| 2008 |
Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 463-7. PMID 18202421 DOI: 10.1200/Jco.2007.13.0344 |
0.475 |
|
| 2008 |
Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology Group. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 112-20. PMID 18165645 DOI: 10.1200/Jco.2006.10.4505 |
0.346 |
|
| 2007 |
Moinpour CM, Donaldson GW, Redman MW. Do general dimensions of quality of life add clinical value to symptom data? Journal of the National Cancer Institute. Monographs. 31-8. PMID 17951229 DOI: 10.1093/Jncimonographs/Lgm007 |
0.338 |
|
| 2007 |
Redman M, Crowley J. Small Randomized Trials Journal of Thoracic Oncology. 2: 1-2. PMID 17410001 DOI: 10.1097/Jto.0B013E31802C8D84 |
0.306 |
|
| 2007 |
Lara P, Redman M, Lenz H, Gordon M, Shibata T, Fukuda H, Tamura T, Saijo N, Natale R, Gandara D. Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124 Journal of Clinical Oncology. 25: 7524-7524. DOI: 10.1200/Jco.2007.25.18_Suppl.7524 |
0.357 |
|
| 2007 |
Davies AM, Mudad R, Moon J, Roberts P, Lau D, Franklin W, Hege K, Redman M, Gandara DR. PD3-1-7: Phase II trial of autologous cancer vaccine, CG8123 (GVAX), in patients with advanced bronchioloalveolar carcinoma (BAC): a Southwest Oncology Group Study (S0310). Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283401.13711.41 |
0.365 |
|
| 2007 |
Lara PN, Redman M, Natale R, Lenz HJ, Gordon M, Shibata T, Fukuda H, Tamura T, Saijo N, Crowley J, Gandara DR. D1-04: Cisplatin (Cis) + etoposide (VP16) vs. cis + irinotecan (CPT11) in extensive stage small cell lung cancer (E-SCLC): Updated pharmacogenomic (SWOG 0124) and comparative toxicity analysis (JCOG 9511 & SWOG 0124) Journal of Thoracic Oncology. 2. DOI: 10.1097/01.Jto.0000283253.77228.1D |
0.383 |
|
| 2006 |
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth N, Lara PN, Le Q, Gumerlock PH, Crowley JJ, Gandara DR. Elevated osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): Analysis of SWOG S0003 Journal of Clinical Oncology. 24: 7198-7198. DOI: 10.1200/Jco.2006.24.18_Suppl.7198 |
0.402 |
|
| 2006 |
Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications for clinical trial design Journal of Clinical Oncology. 24: 7006-7006. DOI: 10.1200/Jco.2006.24.18_Suppl.7006 |
0.43 |
|
| 2003 |
Brumback B, Greenland S, Redman M, Kiviat N, Diehr P. The intensity-score approach to adjusting for confounding. Biometrics. 59: 274-85. PMID 12926712 DOI: 10.1111/1541-0420.00034 |
0.549 |
|
| Show low-probability matches. |